« Insert Therapeutics Agreed to Partner with R&D-Biopharmaceuticals To Develop New Anti-Cancer Drugs | Main | Memory Pharma’s MEM 1003 Failed Phase 2a Bipolar Disorder Clinical Trial »

Mar 5
Dermatrends, Inc. Partners with Teikoku Pharma USA to Develop Transdermal Formula of Anti-Psychotic Drugs

A drug delivery company - Dermatrends, Inc. – has entered into an agreement with Teikoku Pharma USA (8887877) to develop a prototype patch formulation for the transdermal delivery of a widely used anti-psychotic pharmaceutical compound.

The terms of agreement include the following:

  • Dermatrends will be providing the drug delivery technology for transdermal delivery of an anti-psychotic drug that was selected by Teikoku.
  • Dermatrends will utilize its standardized developmental process for effective transdermal delivery.

patch.jpgA world leader in innovative, high-quality drug delivery systems - Teikoku Pharma USA, Inc. – (in addition to its proprietary products) is responsible for the technology and platform of well known branded products including Flector® (Diclofenac Epolamine) and the widely used Lidoderm® (a lidocaine patch marketed by Endo Pharmaceuticals Inc.).

According to Dermatrends CEO Ted Schwarzrock:

"We have produced positive efficacy results for many of our products, including similar compounds to the one we are testing for Teikoku. Our mission is to help demonstrate Dermatrends' patented hydroxide releasing agent (HRA) technology can be combined with the chosen active pharmaceutical ingredient (API) to produce a proprietary pharmaceutical product for our new partner.

There are millions of people who rely on anti- psychotic medication but who cannot be relied upon to take their oral dosage without supervision. Transdermal delivery of this drug represents a large untapped market. We believe that transdermal delivery could be a preferred method of delivery for many patients and their caregivers, representing an important new market opportunity."

Find more details from the press release (a pdf file).

0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Insert Therapeutics Agreed to Partner with R&D-Biopharmaceuticals To Develop New Anti-Cancer Drugs | Main | Memory Pharma’s MEM 1003 Failed Phase 2a Bipolar Disorder Clinical Trial »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb